한빛사 논문
Jutaek Nam1,2,7, Sejin Son1,2,7, Kyung Soo Park2,3, Weiping Zou4,5, Lonnie D. Shea2,3,6 and James J. Moon 1,2,3,5*
1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.
2Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
3Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
4Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA.
5Graduate Program in Immunology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
6Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
7These authors contributed equally: Jutaek Nam, Sejin Son
*To whom correspondence should be addressed.
Abstract
Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and low patient response rates remain major challenges in the clinic. Cancer nanomedicine in combination with immunotherapies offers the possibility to amplify antitumour immune responses and to sensitize tumours to immunotherapies in a safe and effective manner. In this Review, we discuss opportunities for combination immunotherapy based on nanoparticle platforms designed for chemotherapy, photothermal therapy, photodynamic therapy, radiotherapy and gene therapy. We highlight how nanoparticles can be used to reprogramme the immunosuppressive tumour microenvironment and to trigger systemic antitumour immunity, synergizing with immunotherapies against advanced cancer. Finally, we discuss strategies to improve tumour and immune cell targeting while minimizing toxicity and immune-related adverse events, and we explore the potential of theranostic nanoparticles for combination immunotherapy.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기